Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02316340 · ClinicalTrials.gov registry record · Phase 2
Vorinostat Plus Hydroxychloroquine Versus Regorafenib in Colorectal Cancer
A Phase 2 study, sponsored by The University of Texas Health Science Center at San Antonio.
- Completed
- Registry status
- Phase 2
- Development phase
- 42
- Enrollment target
NCT02316340 is a Phase 2 study that has completed, run by The University of Texas Health Science Center at San Antonio. The registered enrollment target is 42 participants.
The verdict
NCT02316340, a Phase 2 study, has completed, sponsored by The University of Texas Health Science Center at San Antonio.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 42 participants
- Enrollment target
Study Summary
This will be a randomized phase II clinical trial of patients with histologic documentation of metastatic colorectal cancer, who have received local and currently approved standard therapies, excluding RGF.
Interventions
- DRUG Regorafenib
- DRUG Vorinostat
- DRUG Hydroxychloroquine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2015-02-11 |
| Est. Completion | 2018-04-16 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02316340
The ClinicalTrials.gov registry entry for NCT02316340 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The University of Texas Health Science Center at San Antonio, which has 378 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Regorafenib is the first listed.
NCT02316340 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02316340 about?
NCT02316340 is a clinical study titled "Vorinostat Plus Hydroxychloroquine Versus Regorafenib in Colorectal Cancer". This will be a randomized phase II clinical trial of patients with histologic documentation of metastatic colorectal cancer, who have received local and currently approved standard therapies, excluding RGF.
What is the current status of trial NCT02316340?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 42 participants. The study started on 2015-02-11. Estimated completion is 2018-04-16.
What interventions are being tested in trial NCT02316340?
The interventions under investigation include: Regorafenib (DRUG), Vorinostat (DRUG), Hydroxychloroquine (DRUG).
Who is sponsoring clinical trial NCT02316340?
This trial is sponsored by The University of Texas Health Science Center at San Antonio, which has 378 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.